LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). The new asset doubles the cancer pipeline for the Salt Lake City-based biotech, which earlier this year completed a phase I/II trial of its lead compound, apatinib mesylate (YN968D1), in solid tumors.